Skip Navigation

Nicole C. Schmitt, MD

Nicole Schmitt, MD

– Acting Associate Professor, Department of Otolaryngology – Head and Neck Surgery, Emory University School of Medicine

– Co-Director, Translational Research, Head & Neck Program, Winship Cancer Institute

Bio-Summary

Dr. Nicole Schmitt's clinical and research work is focused on head and neck surgical oncology and novel therapeutic combinations. She received her MD degree at Washington University School of Medicine in 2006. She completed her general surgery internship as well as her research fellowship and residency in otolaryngology – head and neck surgery at the University of Washington, and completed a fellowship in head and neck surgery and tumor biology at the University of Pittsburgh.

Prior to joining the Emory Otolaryngology faculty in 2020, Dr. Schmitt was a faculty member at Johns Hopkins University, and a special volunteer and principal investigator for the Integrative Therapeutics Program of the Otolaryngology Surgeon Scientist Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health.

Education

Licenses/Certifications

Locations

Current Professional Memberships

Clinical Interests

Research Interests

Recent Publications

"ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer." Ye W, Gunti S, Allen CT, Hong Y, Clavijo PE, Van Waes C, Schmitt NC. Oncoimmunology. 2020 Jan 9;9(1):1710398.

"Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer." Park SJ, Ye W, Xiao R, Silvin C, Padget M, Hodge JW, Van Waes C, Schmitt NC. Oral Oncol. 2019 Aug;95:127-135.

"Cisplatin alters anti-tumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma." Tran L, Allen CT, Xiao R, Moore E, Davis R, Park SJ, Spielbauer K, Van Waes C, Schmitt NC. Cancer Immunol Res 2017;5: 1141-1151.

"PD-1 inhibition minimally impacts cisplatin-induced toxicities in a murine model." Spielbauer K, Cunningham L, Schmitt N. Otolaryngol Head and Neck Surg 2018; 159:343-346.

"Antagonist of cIAP1/2 and XIAP synergizes with radiation therapy and PD-1 blockade to enhance anti-tumor immunity." Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC. Oncoimmunology 2018; 7:e1471440.